Rituximab for the treatment of membranous nephropathy: a single-center experience.

CONCLUSION: The remission rate after rituximab treatment in our cohort of patients with idiopathic membranous nephropathy was lower than in other studies. The reason for this is possibly the application of a single dose of rituximab in the majority of patients, which might have been insufficient in patients with higher proteinuria.
.
PMID: 28664837 [PubMed - as supplied by publisher]

Source: Clinical Nephrology - June 30, 2017 Category: Urology & Nephrology Authors: Rigler AA, Jerman A, Orsag A, Kojc N, Kovač D, Škoberne A, Borštnar Š, Večerić Haler Ž, Avguštin N, Kveder R, Ferluga D, Vizjak A, Lindič J Tags: Clin Nephrol Source Type: research